Uncategorized Archives - Page 12 of 134

FridayMay 10, 2024 9:45 am

Astiva Health Inc. Reshaping Landscape of Healthcare by Prioritizing Patient Engagement

Patient engagement can lead to reduced hospitalizations as well as improved effectiveness, efficiency, quality of health services, quality of life and responsiveness Healthcare industry players should address patient engagement as an imperative strategy Astiva Health recognizes that successful treatment outcomes are largely dependent on the patient, with 90% of treatment success attributed to patient involvement Growing research shows that patient engagement (“PE”) can have a significant impact on the outcome of a patient’s treatment. Recognizing that, Astiva Health is leading the way in offering a Medicare Advantage Prescription Drug (“MAPD”) health plan committed to reshaping the landscape of personalized and comprehensive healthcare…

MondayMay 06, 2024 10:30 am

HealthLynked Corp. (HLYK) Q4, FY2023 Financial Results; Show Bottom-line Improvements, Core Network Application Ramp-Up Expected in 2024

HealthLynked achieved significant optimization in operational expenses, resulting in a 70% reduction in net loss for the fourth quarter and highlighting a period of strategic positioning for future growth HealthLynked's full-year 2023 financial results mark technological advancements, with a focus on core technologies and profitability The company anticipates further performance improvements in the second half of 2024, positioning itself as a leader in healthcare technology HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, recently announced its financial results for the fourth quarter and full year ending December 31, 2023. HealthLynked achieved a significant 70% reduction in net…

MondayMay 06, 2024 9:00 am

Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval

150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications Nutriband raised $8.4 million in a private placement to fund AVERSA Fentanyl through FDA Approval Process Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval. The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine)…

ThursdayMay 02, 2024 10:30 am

Simplifying Healthcare Appointments: How HealthLynked Corp. (HLYK) is Revolutionizing Online Booking with a Patient-Focused Approach

In an era where convenience and efficiency stand as pillars of service delivery, HealthLynked (OTCQB: HLYK) has introduced an innovative online patient booking system, akin to how OpenTable simplifies restaurant reservations. This seamless integration of technology and healthcare is transforming how patients interact with medical services, ensuring that setting up a doctor's appointment is as easy as booking a dinner date. The Booking Process: Tailored for Simplicity and Flexibility HealthLynked's online booking system is designed with the user experience at the forefront. The process is straightforward: patients select their preferred doctor, date, and whether they prefer a morning or afternoon…

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

MondayApr 29, 2024 11:15 am

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

PCPs play pivotal role in successful healthcare approach Evidence shows that primary care helps prevent illness and death Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent, and hard-working primary care physicians (“PCPs”) who play a pivotal role in the healthcare system. “Evidence of the health-promoting influence of primary care has been…

MondayApr 29, 2024 9:00 am

HealthLynked Corp. (HLYK) Is ‘One to Watch’

HealthLynked Corp. is a pioneering healthcare technology company revolutionizing patient care through innovative digital solutions Dr. Michael T. Dent, CEO and Chairman, leads the company with a significant history of successful healthcare management and technology development; his prior leadership at NeoGenomics Laboratories, a company with a current market cap of approximately $2 billion, underscores his ability to scale healthcare solutions in competitive markets HealthLynked’s recently launched HealthLynked Network is a state-of-the-art, cloud-based platform designed to significantly improve the efficiency and quality of patient care by enabling a seamless exchange of medical information The leadership’s deep involvement and commitment are reflected…

WednesdayApr 24, 2024 12:00 pm

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica's dedication to mitigating the devastating impact of sleeping sickness…

TuesdayApr 23, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries Fentanyl, a potent opioid, poses a…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Astiva Health Inc. Reshaping Landscape of Healthcare by Prioritizing Patient Engagement

HealthLynked Corp. (HLYK) Q4, FY2023 Financial Results; Show Bottom-line Improvements, Core Network Application Ramp-Up Expected in 2024

Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval

Simplifying Healthcare Appointments: How HealthLynked Corp. (HLYK) is Revolutionizing Online Booking with a Patient-Focused Approach

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

HealthLynked Corp. (HLYK) Is ‘One to Watch’

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search